(Q36960563)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

4

A Carlo Altamura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

2

Emanuela Mundo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Silvio R Bareggi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

741-753

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Stereoisomers in Psychiatry: The Case of Escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram versus citalopram: the surprising role of the R-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The clinical pharmacokinetics of escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The pharmacokinetics of escitalopram in patients with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram: a review of its use in the management of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram: a review of its use in the management of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The epidemiology of generalized anxiety disorder in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Prevention of relapse in generalized anxiety disorder by escitalopram treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Size and burden of social phobia in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Diagnosis and treatment of obsessive-compulsive disorder and related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram prevents relapse of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram : a review of its use in the management of major depressive and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Discontinuation symptoms in depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram treatment of trichotillomania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram for compulsive buying disorder: a double-blind discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Cost-Effectiveness Analysis of Escitalopram Compared with Paroxetine in Treatment of Generalized Anxiety Disorder in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram: a pharmacoeconomic review of its use in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

Escitalopram in the treatment of anxiety symptoms associated with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.5.741

21 January 2018

Identifiers

DOI

10.1517/17425255.3.5.741

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17916059%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference